Natrium Bicarbonicum Polpharma (Sodium Hydrogen Carbonate)

Natrium Bicarbonicum Polpharma, an alkalinizing agent, is used to correct systemic acid‑base imbalances and related conditions.

• Metabolic acidosis: restores normal blood pH by providing bicarbonate ions, aiding rapid correction in acute settings.
• Systemic acid–base disturbances: buffers excess hydrogen ions to stabilize systemic pH in various clinical scenarios.
• Urine alkalinization: raises urinary pH to facilitate excretion of certain toxins or improve solubility of specific drugs.
• Drug toxicity adjunct: used as part of treatment protocols for specific drug overdoses where urine alkalinization enhances elimination.

• Sodium bicarbonate dissociates in plasma to release bicarbonate ions, which combine with hydrogen ions to form carbonic acid that rapidly converts to carbon dioxide and water. This buffering action raises the extracellular pH, shifting the Henderson‑Hasselbalch equilibrium toward alkalinity and thereby correcting metabolic acidosis. The increased bicarbonate also diffuses into renal tubules, promoting urinary alkalinization and it also assists in maintaining intracellular pH balance.

Sodium bicarbonate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Hypernatremia: elevated serum sodium levels that may cause thirst, hypertension, or neurologic symptoms.
• Metabolic alkalosis: excessive rise in blood pH leading to dizziness, tingling, or muscle cramps.
• Fluid overload: volume expansion that can result in peripheral edema or weight gain.
• Injection site irritation: pain, redness, swelling, or induration at the intravenous or subcutaneous site.

Serious or Rare Side Effects

• Severe metabolic alkalosis: profound pH elevation that may precipitate seizures, cardiac arrhythmias, or respiratory depression.
• Pulmonary edema: accumulation of fluid in the lungs, presenting with dyspnea and reduced oxygenation, especially in patients with heart failure.
• Anaphylactic reaction: rare hypersensitivity characterized by urticaria, bronchospasm, hypotension, and potential anaphylaxis.

When using Natrium Bicarbonicum Polpharma, clinicians should observe several safety measures to minimize risks.

• Electrolyte monitoring: check serum sodium, potassium, and bicarbonate levels regularly during therapy.
• Acid‑base assessment: evaluate arterial blood gases before and after administration to guide dosing.
• Renal function: adjust use in patients with impaired renal clearance to avoid bicarbonate accumulation.
• Cardiovascular status: use cautiously in heart failure or hypertension due to risk of fluid overload.
• Infusion rate: avoid rapid bolus; administer over recommended time to prevent sudden pH shifts.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Sodium bicarbonate can interact with several medications, altering their efficacy or safety.

Major Interactions (Avoid)

• Concurrent alkalinizing agents: combined use may cause severe metabolic alkalosis.
• Potassium‑wasting diuretics: increased risk of hypokalemia due to enhanced urinary potassium loss.
• Acidifying drugs (e.g., acetazolamide): antagonistic effect reducing intended pH correction.

Moderate Interactions (Monitor Closely)

• Loop diuretics: may potentiate electrolyte disturbances, requiring closer monitoring.
• Digitalis glycosides: altered serum potassium can affect cardiac toxicity risk.
• Certain antibiotics (e.g., aminoglycosides): urinary alkalinization may reduce drug efficacy.
• Antihypertensives: fluid and sodium load may blunt blood pressure control.